Indaptus Therapeutics Inc (INDP)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jeffrey A. Meckler
Employees:
5
12 HARTOM STREET, HAR HOTZVIM, JERUSALEM, ISRAEL 777512
97225864657

Indaptus Therapeutics, Inc. develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors.

Data derived from most recent annual or quarterly report
Market Cap 21.638 Million Shares Outstanding8.259 Million Avg 30-day Volume 12.338 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3
Price to Revenue0.0 Debt to Equity0.0 EBITDA-12.981 Million
Price to Book Value1.8575 Operating Margin0.0 Enterprise Value9.937 Million
Current Ratio2.337 EPS Growth0.828 Quick Ratio1.948
1 Yr BETA 1.6716 52-week High/Low 28.83 / 1.89 Profit Margin0.0
Operating Cash Flow Growth60.3602 Altman Z-Score-16.8599 Free Cash Flow to Firm -6.869 Million
Earnings Report2022-11-14
View SEC Filings from INDP instead.

View recent insider trading info

Funds Holding INDP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INDP

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2021-08-09:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 8.01: Other Events
  • 8-K: filed on 2021-07-29:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-23:
    Item 8.01: Other Events
  • 8-K: filed on 2021-07-16:
    Item 8.01: Other Events
  • 8-K: filed on 2021-06-22:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-04-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-03-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-02-08:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2020-12-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-11-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    9.7 Thousand total shares from 2 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MECKLER JEFFREY A CEO AND DIRECTOR

    • Officer
    • Director
    55,066 2022-09-06 5

    ANDERSON GLEN R.

    • 10% Owner
    1,087,048 2022-06-27 1

    SASSI NIR CHIEF FINANCIAL OFFICER

    • Officer
    60,000 2022-02-25 1

    LITCHEV BOYAN VESSELINOV CHIEF MEDICAL OFFICER

    • Officer
    90,000 2022-02-01 2

    NEWMAN MICHAEL JAMES CSO AND DIRECTOR

    • Officer
    • Director
    • 10% Owner
    1,368,356 2022-01-31 2

    LINSCOTT WALT ADDISON CHIEF BUSINESS OFFICER

    • Officer
    45,850 2022-01-26 1

    GILBERT MARK JOHN

    • Director
    20,000 2021-12-01 2

    HAYES WILLIAM B

    • Director
    13,750 2021-08-04 0

    O'CALLAGHAN BRIAN

    • Director
    13,750 2021-08-04 0

    MADDALUNA ANTHONY J

    • Director
    13,750 2021-08-04 0

    POMERANTZ ROGER

    • Director
    41,000 2021-08-04 0

    KARAH HILA

    • Director
    13,750 2021-08-04 0

    LEE HOONMO

    • Director
    13,750 2021-08-04 0

    NAVON NADAV CHIEF OPERATING OFFICER

    • Officer
    0 2020-09-16 0

    KOZARICH JOHN W

    • Director
    0 2020-07-15 0

    GENDREAU R MICHAEL CHIEF MEDICAL OFFICER

    • Officer
    0 2020-02-17 0

    DEXCEL PHARMA TECHNOLOGIES LTD.

    OREN DAN

    • 10% Owner
    No longer subject to file 2020-01-31 0

    SILBERMAN ISSAC

    • Director
    4,000 2019-11-19 0

    BIANCO GIL

    • Director
    0 2019-06-28 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MECKLER JEFFREY A - Director - Officer CEO AND DIRECTOR

    2022-09-08 09:00:30 -0400 2022-09-07 P 8,632 $2.57 a 55,066 direct

    MECKLER JEFFREY A - Director - Officer CEO AND DIRECTOR

    2022-09-08 09:00:30 -0400 2022-09-06 P 1,060 $2.44 a 46,434 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    INDAPTUS THERAPEUTICS INC INDP 2022-09-08 15:15:04 UTC -32.3492 34.6692 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-08 14:45:03 UTC -32.3492 34.6692 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-08 14:15:03 UTC -32.3492 34.6692 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-08 13:45:03 UTC -32.3492 34.6692 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-08 13:15:03 UTC -32.3492 34.6692 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-08 12:45:03 UTC -32.3492 34.6692 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 22:15:05 UTC -32.3492 34.6692 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 21:45:05 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 21:15:04 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 20:45:03 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 20:15:05 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 19:45:04 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 19:15:04 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 18:45:04 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 18:15:05 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 17:45:04 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 17:15:05 UTC -32.3237 34.6437 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 16:45:04 UTC -32.4852 34.8052 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 16:15:04 UTC -32.4852 34.8052 150000
    INDAPTUS THERAPEUTICS INC INDP 2022-09-07 15:45:04 UTC -32.4852 34.8052 150000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund INDP -1700.0 shares, $-4437.0 2022-06-30 N-PORT

    Elevate your investments